Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...
Investor's Business Daily on MSN18h
Biotech Stocks Take A Tariffs Hit. Pharmaceuticals Are Exempt — For Now.Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...
Leerink Partners analyst Geoff Porges maintained a Buy rating on Regeneron (NASDAQ:REGN) on Tuesday, setting a price target of ...
Should Regeneron wish to compete, they will have to lower their prices, thereby eating into their profit margins. Interestingly, at the recent Leerink Global Healthcare Conference, the CFO Chris ...
The Cambridge, Massachusetts-based biotech had divested its cell therapy R&D programs to Regeneron for $5 million upfront in early 2024. As the Leerink team noted, the company’s remaining ...
With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...
The acquisition could save Bristol future profit-sharing costs in Abecma, according to Leerink analyst David Risinger. Last year, 2seventy sold all its experimental cell therapies to Regeneron ...
But given the miss in the TRuE-PN2, the Leerink team figures Incyte may be ... Recent biologics approvals in PN, including those for Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio ...
In a note sent to investors Tuesday, Leerink Partners analyst Daina Graybosch ... as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers Squibb] manufactures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback